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Genetic Overlap Between Attention-Deficit/
Hyperactivity Disorder and Bipolar Disorder:
Evidence From Genome-wide Association
Study Meta-analysis
Kimm J.E. van Hulzen, Claus J. Scholz, Barbara Franke, Stephan Ripke, Marieke Klein,
Andrew McQuillin, Edmund J. Sonuga-Barke, PGC ADHD Working Group, John R. Kelsoe,
Mikael Landén, Ole A. Andreassen, PGC Bipolar Disorder Working Group, Klaus-Peter Lesch,
Heike Weber, Stephen V. Faraone, Alejandro Arias-Vasquez, and Andreas Reif
ABSTRACT
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BPD) are frequently co-
occurring and highly heritable mental health conditions. We hypothesized that BPD cases with an early age of
onset (#21 years old) would be particularly likely to show genetic covariation with ADHD.
METHODS: Genome-wide association study data were available for 4609 individuals with ADHD, 9650 individuals
with BPD (5167 thereof with early-onset BPD), and 21,363 typically developing controls. We conducted a cross-
disorder genome-wide association study meta-analysis to identify whether the observed comorbidity between ADHD
and BPD could be due to shared genetic risks.
RESULTS: We found a significant single nucleotide polymorphism–based genetic correlation between ADHD and
BPD in the full and age-restricted samples (rGfull 5 .64, p 5 3.13 3 10
–14; rGrestricted 5 .71, p 5 4.09 3 10
–16). The
meta-analysis between the full BPD sample identified two genome-wide significant (prs7089973 5 2.47 3 10
–8;
prs11756438 5 4.36 3 10
–8) regions located on chromosomes 6 (CEP85L) and 10 (TAF9BP2). Restricting the analyses
to BPD cases with an early onset yielded one genome-wide significant association (prs58502974 5 2.11 3 10
–8) on
chromosome 5 in the ADCY2 gene. Additional nominally significant regions identified contained known expression
quantitative trait loci with putative functional consequences for NT5DC1, NT5DC2, and CACNB3 expression,
whereas functional predictions implicated ABLIM1 as an allele-specific expressed gene in neuronal tissue.
CONCLUSIONS: The single nucleotide polymorphism–based genetic correlation between ADHD and BPD is
substantial, significant, and consistent with the existence of genetic overlap between ADHD and BPD, with potential
differential genetic mechanisms involved in early and later BPD onset.
Keywords: Attention-deficit/hyperactivity disorder, bipolar disorder, cross-disorder meta-analysis, genetic correlation,
genetic overlap, GWAS
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Attention-deficit/hyperactivity disorder (ADHD) is the most
frequent neuropsychiatric disorder in childhood and frequently
persists into adulthood. Bipolar disorder (BPD) is among the
most prevalent mental diseases in adulthood. Both disorders
are highly heritable (1,2). However, in both cases the mode of
inheritance is complex and polygenic (3). Although differing
from one another with regard to core signs and symptoms,
age of onset, presentation, and treatment response, the two
disorders share several clinical features. This is especially the
case for the manic phase of BPD, which is associated with
irritability, increased impulsivity, distractibility, and restless-
ness (4). Furthermore, ADHD often copresents with depression
(5), a core feature of BPD. In adulthood, when BPD is most
commonly diagnosed, co-occurrence of the two disorders
occurs more often than would be expected by chance (6).
For patients with BPD rates of ADHD vary between 9.5% and
28%, depending on study characteristics (7,8). The rate of
BPD in adult ADHD has been estimated at around 20% (7).
Meta-analyses of family studies confirm elevated rates of BPD
in first-degree relatives of ADHD patients and vice versa (8).
Although a shared genetic basis for ADHD and BPD seems
plausible given the above, molecular genetic studies thus far
provide limited evidence for this (9–11). For instance, risk-allele
frequencies of candidate genes, identified through prior ADHD
genome-wide association studies (GWASs), are not increased
in BPD. This failure to find a shared genetic signal may be due
to prior studies’ lack of statistical power and to the limited set
of polymorphisms examined. To address these shortcomings,
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a genome-wide cross-disorder meta-analysis of BPD and
ADHD was conducted in a large sample of individuals with
BPD, indivduals with ADHD, and in typically developing
control subjects from the Psychiatric Genomics Consortium.
Because ADHD is a childhood onset disorder (prior to 12 years
of age), we hypothesized that the overlap would be most
obvious in BPD cases with a relatively early onset (age of
onset #21 years old), as this group could be assumed to have
a more neurodevelopmental etiology (8). Restricting the age
range of the sample to those with an onset#21 years of age may
also increase the power for gene finding because it could reduce
heterogeneity (12). We thus performed analyses with the total
number of BPD cases as well as the age-restricted set. GWAS
meta-analysis top findings were further characterized using
expression quantitative trait locus (eQTL) analysis to investigate
potential functional consequences for gene expression.
METHODS AND MATERIALS
Samples
Cases, controls, and family-based samples assembled for
previous genome-wide Psychiatric Genomics Consortium
analyses of individual-level data were included in the current
analysis (13,14). A description of individual study data con-
tributions and genotyping platforms is included in
Supplemental Tables S1A and S1B. The ADHD sample
comprised 4609 cases and 8519 controls. The full BPD
sample comprised 9650 cases and 12,844 controls. For tests
of the age of onset hypothesis we restricted the BPD sample
to cases with an age of onset #21 years of age. This reduced
the number of cases to 5167 (restricted sample). All available
controls from the BPD samples were included in the age-
restricted sample to maximize power. Control individuals that
featured in both the ADHD and BPD samples were identified
and removed prior to analysis.
Genetic Analysis
Raw genotype and phenotype data for each study was
uploaded to a central server and processed through the same
quality control, imputation, and analysis process to ensure
comparability between the samples. The quality control and
analysis pipeline is described elsewhere (3).
Statistical Analysis
Linkage disequilibrium (LD) score regression was used to
estimate the single nucleotide polymorphism (SNP)–based
genetic correlation (rG) between the ADHD and both BPD
samples. For LD score regression, each data set underwent
additional filtering. Only markers overlapping with HapMap
Project Phase 3 SNPs and passing the following filters were
included: INFO (imputation) score . 0.9, study missingness of
0, and minor allele frequency .1% (where available). Indels
and strand-ambiguous SNPs were removed.
The analysis was conducted using a two-step procedure
with the LD scoring analysis package (https://github.com/
bulik/ldsc) (15). An unconstrained regression was run to
estimate the regression intercepts for each phenotype, fol-
lowed by an analysis with regression intercepts constrained to
those estimated in the first step and an unconstrained
covariance intercept (we took steps to exclude overlapping
samples). Standard errors were estimated using a block
jackknife procedure and used to calculate p values.
GWAS was initially performed for each ADHD study sepa-
rately (n 5 8). Four multidimensional scaling components were
included to account for potential population stratification.
GWAS was then also performed for each BPD study sepa-
rately (n 5 12). In this case a total of seven multidimensional
scaling components (both total and restricted samples) were
used in the analysis in order to correct for potential population
stratification. These GWASs were free from genomic inflation
as judged by quantile-quantile plots (data not shown). For
each disorder, results were then combined in a disorder-
specific meta-analysis. Finally, results from the disorder-
specific meta-analyses were combined in cross-disorder
meta-analyses for both the primary and the age-restricted
samples. For all meta-analyses, we applied a weighted
Z-score approach using PLINK 1.07 (http://pngu.mgh.har
vard.edu/purcell/plink/index.shtml), in which weights
equaled the inverse of the regression coefficient’s standard
error (16). This strategy assumed a fixed-effects model, in
which all studies/disorders had the same direction of effect,
with weights indicating the sample size and imputation
accuracy of the disease-specific studies. The fixed effects
model was compared with a genome-wide random-effects
model in which studies/disorders were allowed to have a
different direction of effect.
Prediction of Allele-Specific Effects on Transcription
The overlap between polymorphic loci with microRNA binding
sites was examined using the PolymiRTS 3.0 database (17). To
check for the known influence of identified SNPs on gene
expression, we searched a database of cis-acting eQTLs
defined with RNA sequencing data of lymphoblastoid cell
lines from 462 individuals, most of which were also examined
in the 1000 Genomes Phase I dataset (18). Allele-specific
transcription factor binding sites (TFBSs) were predicted with
the web-based tool MatInspector version 2.1 (http://www.
genomatix.de/online_help/help_matinspector/matinspector_
help.html) (19). TFBS searches were performed for all
promoter regions (40 kb upstream) of the top 100 SNPs
identified in the full and the age-restricted meta-analyses
(i.e., each allele flanked by 10 base pairs up- and down-
stream sequence). Sequences with a transcription
factor–specific matrix core similarity of at least 0.75 were
defined as potentially containing the respective TFBS.
RESULTS
SNP-Based Genetic Correlation
The SNP-based rG between ADHD and BPD was substantial
and significant for both the full and age-restricted samples.
Interestingly, the rG was higher for the age-restricted sample as
compared with the full sample (rGfull 5 .64, SE 5 .02, p 5 3.13
3 10–14; rGrestricted 5 .71, SE 5 .02, p 5 4.09 3 10
–16; Table 1).
Full Sample. Figure 1A shows the Manhattan plot of the
primary cross-disorder meta-analysis, and Supplemental
Meta-analysis of ADHD and BPD GWAS
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Figure S1A shows the corresponding quantile-quantile plot.
Two independent loci, located on chromosomes 6 and 10,
reached genome-wide significance (p , 5 3 10–8). The
strongest signal (p 5 2.47 3 10–8) was for SNP rs7089973,
located on chromosome 10 in an intronic region of the TAF9B
RNA polymerase II, TATA box binding protein–associated
factor, 31 kDa pseudogene 2 gene (TAF9BP2; Figure 2A),
which is a pseudogene of a yet unknown function. SNP
rs7089973 is in LD with SNPs in the TruB pseudouridine
synthase homolog 1 gene (TRUB1; best p 5 8.89 3 10–6) and
with the family with sequence similarity 160 member B1 gene
(FAM160B1; best p 5 5.45 3 10–8).
On chromosome 6, the strongest signal was for SNP
rs11756438, located in an intronic region of the centrosomal
protein 85 kDa–like gene (CEP85L; p 5 4.36 3 10–8;
Figure 2B) encoding a protein of unknown function. Further-
more, rs11756438 is in LD with SNPs in the bromodomain
containing 7 pseudogene 3 gene (BRD7P3; best p 5 9.39 3
10–7), the phospholamban gene (PLN; best p 5 7.25 3 10–7),
and the solute carrier family 35, member F1 gene (SLC35F1;
best p 5 1.00 3 10–5). Both associated regions showed the
same direction of effect in ADHD and BPD. The disorder-
specific contribution to each genome-wide significant locus
can be found in Table 2, and forest plots from individual
GWASs are shown in Supplemental Figure S5. Top-ranked
SNPs for this analysis (p , 10–6) are summarized in
Supplemental Table S3.
Age-Restricted BPD Sample. The Manhattan plot for the
age-restricted analysis is shown in Figure 1B; the respective
Table 1. Results From the Univariate Heritability Analysis and Genetic Correlation Between Data From ADHD and BPD
Complete and Age-Restricted Samples
BPD Cohort n (Cases/Controls) Heritability SE Genetic Correlation With ADHD SE Z Score p Value
Age Restricted 5167/12,844 0.119 0.023 0.7062 0.087 7.593 4.09 3 10–16
Full Sample 9650/12,844 0.068 0.024 0.6392 0.084 8.136 3.13 3 10–14
Attention-deficit/hyperactivity disorder (ADHD): ncases 5 4609 and ncontrols 5 8519; single nucleotide polymorphism–based h2 (observed) 5
0.0652 (SE 5 0.0279).
BPD, bipolar disorder; h2, heritability.
Figure 1. Manhattan plot of the (A) primary and (B) restricted cross-disorder meta-analyses. Only single nucleotide polymorphisms with p values #.05 are
shown; horizontal lines show threshold for genome-wide significance (p , 5 3 10–8 in red) and suggestive association (p , 1 3 10–6 in blue).
Meta-analysis of ADHD and BPD GWAS
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quantile-quantile plot is provided in Supplemental Figure S1B.
One SNP on chromosome 5 reached genome-wide signifi-
cance; forest plots of results from individual GWAS are shown
in Supplemental Figure S5. The strongest signal (p 5 2.47 3
10–8) was observed for SNP rs58502974, located in an intron
of the adenylate cyclase 2 (brain) (ADCY2) gene (Figure 2C).
The product of this gene is a member of the family of
adenylate cyclases, which are membrane-associated enzymes
that catalyze the formation of the secondary messenger
cyclic adenosine monophosphate (cAMP). Top-ranked SNPs
Figure 2. (A) Regional plot for genome-wide significant locus on
chromosome (chr) 10 for the primary meta-analysis. (B) Regional plot for
genome-wide significant locus on chr6 for the primary meta-analysis. (C)
Regional plot for genome-wide significant locus on chr5 for the restricted
meta-analysis. Results are shown as –log (p value) for genotyped and
imputed single nucleotide polymorphisms (SNPs). The SNP showing
strongest association is shown in the purple circle. The color of the
remaining markers reflects r2 of the strongest associated SNP. The
recombination rate is plotted in blue. cM/Mb, centimorgan/megabase.
Meta-analysis of ADHD and BPD GWAS
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for this analysis (p , 10–4) are summarized in Supplemental
Table S3.
Allele-Specific Transcriptional Activity
None of the top 100 associated SNPs in the primary and
restricted analyses (Supplemental Table S3) were listed in the
GEUVADIS (Genetic European Variation in Disease) database
of cis-eQTLs defined in lymphoblastoid cell lines that were
mainly derived from the 1000 Genomes sample (18). To
estimate the potential eQTL function in other tissues, direct
bioinformatics prediction was thus used and found differential
binding of transcription factors for 13 markers in the primary
and four in the restricted GWAS, which involved neurorelevant
transcription factors at seven and one sites, respectively
(Supplemental Table S5). A notable finding among those was
for the gene ABLIM1. Allele-specific binding sites of micro-
RNAs at the three prime untranslated region (30-UTR) of family
with sequence similarity 160, member B1 (FAM160B1) tran-
scripts were also observed (Supplemental Table S5).
Extending this analysis to evaluate top-ranked SNPs (p ,
10–4) for effects on transcriptional activity, we queried the
GEUVADIS database (18) for known eQTLs. Of the 4806 SNPs
displaying a trend toward association (p , 1 3 10–4) in
one of the two analyses, 192 indeed were known eQTLs
(Supplemental Table S4). Of those, 74 markers influenced
the expression of 50-nucleotidase domain containing 2
(NT5DC2); the expression of its homolog NT5DC1 was
modulated by 17 SNPs. Two SNPs were found to influence
the expression of the calcium-channel, voltage-dependent,
beta 3 subunit (CACNB3). The accumulation of eQTLs at the
NT5DC loci especially may be explained by LD. Indeed, when
we tested the total number of eQTLs, it did not exceed
expectation in either the full or the restricted analysis (odds
ratioprimary 5 0.91, pprimary 5 0.27; odds ratiorestricted 5 0.97,
pprestricted 5 0.84).
DISCUSSION
In this study, we set out to identify shared genetic risk factor
for ADHD and BPD through cross-disorder meta-analysis of
the existing GWAS samples from the Psychiatric Genomics
Consortium. We hypothesized that overlap between the dis-
orders might be most pronounced in BPD cases with an early
age of onset, and that restricting the analysis to samples with
an onset #21 years of age would increase the power of gene
finding by reducing heterogeneity (8). Our findings clearly show
the substantial and significant genetic correlation between ADHD
and BPD, which supports the existence of genome-wide
significant, shared genetic risk variants for ADHD and BPD
(rGfull 5 .64, SE 5 .08, p 5 3.13 3 10
–14; rGrestricted 5 .71,
SE 5 .09, p 5 4.09 3 10–16; Table 1). We contrasted these
results by estimating the genetic correlation between ADHD and
BPD using previously published data sets and found the same
correlation pattern (Supplemental Table S2).
In the full sample, we found two genome-wide significant
loci and 10 with suggestive evidence of association (p , 10–6;
Supplemental Table S3). Although the statistical power was
potentially lower in the age-restricted sample, one significant
finding was observed. The region identified was different from
the top findings in the primary analysis, raising the possibility
of development-specific gene activity in these two condi-
tions. When specifically considering the BPD analyses
(Supplemental Table S3; also compare Supplemental
Figure S2A, B), it becomes clear that almost all top cross-
disorder SNPs have lower p values in the age-restricted BPD
sample as compared with the full BPD sample, despite its
lower power. This might point to a stronger genetic compo-
nent of early-onset BPD and consequently a different etiology
as compared with late-onset BPD (20). However, these find-
ings are still preliminary, as addressing this issue was not the
major aim of our analysis, and further work is clearly needed to
adequately answer such questions.
Our top hit in the full analysis was present on chromosome
10 in the gene TAF9BP2. This being a pseudogene of
unknown function, we cannot speculate about its potential
involvement in the ADHD-BPD covariation. TRUB1, which
includes variants in LD with the top SNP, may constitute a
potential candidate gene; its product is a member of the
pseudouridine synthase gene family and may function as RNA
chaperone, altering aspects of messenger RNA metabolism
known to be affected by RNA structure (21). The protein
encoded by CEP85L, suggested to be involved by the hit
on chromosome 6, was identified as a breast cancer antigen
(22); the gene was also associated in a meta-analysis with the
myocardial repolarization (23,24), the latter lending some
support to the notion that the gene’s product is involved in
neural conduction. This is the first time that genes in these loci
are associated with psychiatric diseases, so the mechanisms
by which variants in those might affect disease risk remain
elusive. Our eQTL analyses did not provide evidence for a
direct effect of the variation on the expression of the impli-
cated genes or surrounding genes in LD with the hits.
Furthermore, the functions of these genes are not well
described, highlighting the need for further research.
The best hit found in the age-restricted sample is more
obviously functionally significant. ADCY2, which codes for
Table 2. Association Results Showing Effect Size and p for Genome-wide Significant Loci by Disorder for the Primary and
Restricted Meta-analyses
SNP Location (bp:chr) A1/A2 MAF ORADHD pADHD SEADHD ORBPD pBPD SEBPD ORMA pMA Gene
Primary Meta-analysis
rs7089973 10:116569565 A/C 0.36 0.90 1.56 3 10–3 0.03 0.90 4.39 3 10–6 0.02 0.90 2.47 3 10–8 TAF9BP2
rs11756438 6:118993632 A/C 0.34 1.11 6.14 3 10–4 0.03 1.11 1.85 3 10–5 0.02 1.10 4.36 3 10–8 CEP85L
Age-Restricted Meta-analysis
rs58502974 5:7755900 A/T 0.44 1.14 1.84 3 10–5 0.03 1.11 2.33 3 10–4 0.03 1.13 2.11 3 10–8 ADCY2
ADHD, attention-deficit/hyperactivity disorder; bp, base pair; BPD, bipolar disorder; chr, chromosome; MA, meta-analysis; MAF, minor allele
frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
Meta-analysis of ADHD and BPD GWAS
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adenylate cyclase 2, is a key regulator of cAMP metabolism
and thus of second messaging by activating protein kinase A,
thereby triggering cAMP response element binding protein
phosphorylation (25). Both the protein kinase A and cAMP
response element binding protein pathways (26,27) have
been implicated in BPD, and CREB1 is a well-documented
candidate gene for BPD (28). Recently, an SNP in ADCY2 was
also found to be genome-wide significantly associated with
BPD (29). There is a vast literature on disturbances of
serotonin and dopamine signaling in ADHD; both monoamines
target G protein–coupled receptors that use ADCY2 in their
signal transduction cascades, so it is conceivable that this
protein is also relevant to ADHD. As this association became
significant (p 5 4.5 3 10–8) when restricting the BPD sample
to an age of onset #21 years old, the signal likely may be
associated with a more neurodevelopmental form of BPD. One
hypothesis for future research is that adenylate cyclase
signaling is a core mechanism mediating the comorbidity
between ADHD and BPD.
Our primary meta-analysis yielded 10 suggestive loci (p ,
10–6). In addition to the aforementioned genes, these loci
comprise the following candidate genes, each supported by at
least three suggestive associations: On chromosome 1, we
observed a suggestive association with the retinoid X recep-
tor, gamma gene (RXRG). RXRG codes for retinoid receptor
gamma—a regulator of dopamine signaling, cocaine
response, and affective behaviors in mice (30,31). This makes
it an attractive candidate for both BPD and ADHD. The gene
has been suggested to have an effect on hippocampal volume
by QTL analysis in mice (32) and has been associated with
sensation seeking (33), a personality trait associated with
combined-type ADHD (34). On chromosome 3, a signal for
the neuroligin 1 gene (NLGN1) was also found. The neuroligin
protein family has already been implicated in a wide range of
neuropsychiatric disorders including autism, schizophrenia,
and BPD (35).
Presence of eQTLs was evaluated in SNPs with association
p values ,10–4 in either of the cross-disorder GWAS meta-
analyses (Supplemental Table S5). Several interesting candi-
date genes for ADHD-BPD covariation were found to be
regulated by multiple SNPs in our list serving as eQTLs. Of
greatest interest are the findings implicating two members of
the NT5DC family, a family of haloacid dehalogenase–type
phosphatases (36). NT5DC1 has been associated with BPD in
several studies, showing the strongest association with the
disorder in National Institute of Mental Health Genetics
Initiative bipolar pedigrees (37). Importantly, we recently
observed an association between rare variants in this gene
and adult ADHD (38). NT5DC2 has previously been found
associated with schizophrenia; furthermore, NT5DC2 is a
target of microRNA-137 and is differentially methylated as a
function of childhood maltreatment in BPD patients (39).
Another interesting finding was for CACNB3, which codes
for a voltage-gated calcium channel involved in neuronal
morphology and differentiation; its transcript is targeted by
microRNA-34a, which is upregulated in cerebellum of bipolar
patients (40). Allelic variation in ABLIM1, which has previously
been associated with novelty seeking, harm avoidance,
reward, and alcohol dependence (41), also appears to be a
plausible finding.
Our finding that putative promoter regions containing the
top-ranked associated SNPs do not contain known eQTLs
was against our predictions of allele-specific effects on tran-
scription. This discordance may, on the one hand, be attrib-
uted to the known high false positive rate of pattern searches
with position-specific scoring matrices (19). On the other hand,
the eQTL dataset was derived from analyses of lymphoblas-
toid cell lines (18), and it is therefore conceivable that the
allele-specific TFBSs may serve as functional eQTLs in a
different tissue context.
The findings described here need to be interpreted in the
light of several caveats. The differential diagnosis especially
between BPD and adult ADHD can be challenging. Although
this does not affect the ADHD sample, which was ascertained
in childhood, it might pose a problem for the BPD sample:
some shared signals might be due to patients with adult ADHD
having falsely received a diagnosis of BPD. Given that all
studies included here relied on DSM inclusion criteria, we are
confident that misdiagnosis is at least not common enough to
account for genome-wide significant hits. Ethnic heterogeneity
might influence the results as well, although we aimed to
control for this by including multidimensional scaling compo-
nents in every GWAS included in the meta-analyses. Finally,
sample sizes in our cross-disorder analyses were still rather
small for complex genetic traits. This was particularly damag-
ing in the restricted analysis, where the reduction in sample
size masked the potential increase in power due to the
reduction in etiological heterogeneity (discussed above).
In conclusion, we provide evidence for the genetic overlap
between ADHD and BPD. This genome-wide SNP-based
genetic overlap confirms the involvement of pathways such
as G protein–coupled signaling already known for their role in
hyperactivity and/or emotional behaviors, and implicate a new
candidate pathway (i.e., messenger RNA stability) in the
pathophysiology of both ADHD and BPD.
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